Promising new treatments for cytomegalovirus retinitis.
Polis
M A
MA
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892-1880, USA.
Masur
H
H
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000077404:Cidofovir; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy*; D003596:Cytosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004343:Drug Implants; D017245:Foscarnet / Q000008:administration & dosage / Q000627:therapeutic use*; D015774:Ganciclovir / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D015552:Injections, Intralesional; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000627:therapeutic use*
D004343:Drug Implants; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D017245:Foscarnet; D003596:Cytosine; D000077404:Cidofovir; D015774:Ganciclovir